Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase

Bailly, 2012, Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy, Chem Rev, 112, 3611, 10.1021/cr200325f

Pogorelcnik, 2013, Recent advances in the development of catalytic inhibitors of human DNA topo-isomerase IIα as novel anticancer agents, Curr Med Chem, 20, 694, 10.2174/092986713804999402

Ezoe, 2012, Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor, Int J Environ Res Public Health, 9, 2444, 10.3390/ijerph9072444

Chen, 2012, Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs, Drug Discov Ther, 6, 230

Kang, 2011, A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide, Neoplasia, 13, 1043, 10.1593/neo.11972

Batsuren, 1981, Arylnaphthalene lignans of Haplophyllum dauricum. The structure of daurinol, Chem Nat Compd, 17, 223, 10.1007/BF00568506

Graham, 2000, Plants used against cancer - an extension of the work of Jonathan Hartwell, J Ethnopharmacol, 73, 347, 10.1016/S0378-8741(00)00341-X

Hande, 1998, Etoposide: four decades of development of a topoisomerase II inhibitor, Eur J Cancer, 34, 1514, 10.1016/S0959-8049(98)00228-7

Park, 2014, Regioselective route for arylnaphthalene lactones: convenient synthesis of taiwanin C, justicidin E, and daurinol, Tetrahedron Lett, 55, 818, 10.1016/j.tetlet.2013.12.014

Lanzetta, 1979, An improved assay for nanomole amounts of inorganic phosphate, Anal Biochem, 100, 95, 10.1016/0003-2697(79)90115-5

Kang, 2010, The three proline residues (P25, P242, and P434) of Agrobacterium CP4 5-enolpyruvylshikimate-3-phosphate synthase are crucial for the enzyme activity, Plant Biotechnol Rep, 4, 329, 10.1007/s11816-010-0150-3

Jun, 2011, Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy-1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor, Eur J Med Chem, 46, 1964, 10.1016/j.ejmech.2011.01.011

Robinson, 1993, Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II, Biochemistry, 32, 3638, 10.1021/bi00065a016

Kang, 2007, The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme, Biol Pharm Bull, 30, 2352, 10.1248/bpb.30.2352

Kang, 2011, Cell and nuclear enlargement of SW480 cells induced by a plant lignan, arctigenin: evaluation of cellular DNA content using fluorescence microscopy and flow cytometry, DNA Cell Biol, 30, 623, 10.1089/dna.2010.1199

Kang, 2010, Flow cytometric fluorescence pulse width analysis of etoposide-induced nuclear enlargement in HCT116 cells, Biotechnol Lett, 32, 1045, 10.1007/s10529-010-0277-x

Roca, 1995, The mechanisms of DNA topoisomerases, Trends Biochem Sci, 20, 156, 10.1016/S0968-0004(00)88993-8

Larsen, 2003, Catalytic topoisomerase II inhibitors in cancer therapy, Pharmacol Ther, 99, 167, 10.1016/S0163-7258(03)00058-5

Eastman, 2004, Cell cycle checkpoints and their impact on anticancer therapeutic strategies, J Cell Biochem, 91, 223, 10.1002/jcb.10699

Masai, 2010, Eukaryotic chromosome DNA replication: where, when, and how?, Annu Rev Biochem, 79, 89, 10.1146/annurev.biochem.052308.103205

DeGregori, 1995, Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes, Mol Cell Biol, 15, 4215, 10.1128/MCB.15.8.4215

Gui, 2011, D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα, Invest New Drugs, 29, 800, 10.1007/s10637-010-9425-3

Schmeisser, 2013, Mitochondrial hormesis links low-dose arsenite exposure to lifespan extension, Aging cell, 12, 508, 10.1111/acel.12076

Dengg, 2004, Caenorhabditis elegans as model system for rapid toxicity assessment of pharmaceutical compounds, J Pharmacol Toxicol Methods, 50, 209, 10.1016/j.vascn.2004.04.002

van den Heuvel, 2012, C. elegans cell cycle analysis, Methods Cell Biol, 107, 265, 10.1016/B978-0-12-394620-1.00009-6